Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 20,800 shares, a decline of 6.3% from the June 30th total of 22,200 shares. Based on an average daily volume of 9,100 shares, the days-to-cover ratio is currently 2.3 days. Currently, 0.4% of the shares of the company are short sold.
Aprea Therapeutics Stock Performance
Shares of APRE stock traded down $0.08 on Tuesday, hitting $3.92. The stock had a trading volume of 6,323 shares, compared to its average volume of 20,106. The firm has a market capitalization of $21.29 million, a price-to-earnings ratio of -1.14 and a beta of 1.04. The stock’s 50 day moving average is $4.26 and its 200-day moving average is $5.42. Aprea Therapeutics has a 52-week low of $2.95 and a 52-week high of $8.85.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.11. The firm had revenue of $0.38 million for the quarter. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. Equities analysts expect that Aprea Therapeutics will post -2.57 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Further Reading
- Five stocks we like better than Aprea Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What Is WallStreetBets and What Stocks Are They Targeting?
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Airline Stocks – Top Airline Stocks to Buy Now
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.